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Abstract
LARGE is a glycosyltransferase involved in glycosylation of α-dystroglycan (α-DG).
Absence of this protein in the LARGEmyd mouse results in α-DG hypoglycosylation, and is
associated with central nervous system abnormalities and progressive muscular dystrophy.
Up-regulation of LARGE has previously been proposed as a therapy for the secondary dys-
troglycanopathies: overexpression in cells compensates for defects in multiple dystroglyca-
nopathy genes. Counterintuitively, LARGE overexpression in an FKRP-deficient mouse
exacerbates pathology, suggesting that modulation of α-DG glycosylation requires further
investigation. Here we demonstrate that transgenic expression of human LARGE (LARGE-
LV5) in the LARGEmyd mouse restores α-DG glycosylation (with marked hyperglycosylation
in muscle) and that this corrects both the muscle pathology and brain architecture. By quan-
titative analyses of LARGE transcripts we also here show that levels of transgenic and
endogenous LARGE in the brains of transgenic animals are comparable, but that the trans-
gene is markedly overexpressed in heart and particularly skeletal muscle (20–100 fold over
endogenous). Our data suggest LARGE overexpression may only be deleterious under a
forced regenerative context, such as that resulting from a reduction in FKRP: in the absence
of such a defect we show that systemic expression of LARGE can indeed act therapeuti-
cally, and that even dramatic LARGE overexpression is well-tolerated in heart and skeletal
muscle. Moreover, correction of LARGEmyd brain pathology with only moderate, near-physi-
ological LARGE expression suggests a generous therapeutic window.
Introduction
Dystroglycan was originally identified as the central component of the dystrophin associated
glycoprotein complex (DAGC) in skeletal muscle, but has since been shown to be one of the
main receptors linking basement membranes to the cell surface in a wide variety of tissues, via
association with components such as laminin [1], perlecan, agrin [2] in muscle, neurexin in the
brain [3], pikachurin in the eye [4] and most recently Slit [5]. Dystroglycan consequently plays
a primary role in the deposition, organisation and turnover of these specialised matrices, medi-
ating basement membrane formation [6, 7], synaptic plasticity [8, 9], neuronal cytoskeletal
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remodelling [10, 11], axon guidance [5, 12], three-dimensional organisation of radial glia [13],
cell adhesion [14], and acting as a scaffold to facilitate localisation of signalling molecules close
to their sites of action [15].
Dystroglycan is comprised of two subunits, α- and β-DG; both products of a single gene
(Dag1), translated as a single protein and post-translationally cleaved. Whilst β-dystroglycan is
recognised as a transmembrane adhesion protein with many interacting partners [16, 17],
α-DG is a heavily-glycosylated peripheral membrane protein that consists of two globular
domains connected by an elongated central domain [18]. This central domain is extensively O-
mannosylated on Ser/Thr residues, and glycoepitopes in this region contribute to the stability
of the protein but also govern linkage to laminin-G-like (LG) domain-containing extracellular
matrix proteins [2, 19], with binding strength and specificity mediated both by the nature and
extent of glycosylation.
Defects in glycosylation of α-DG are thus central to the disease process in a group of disor-
ders now referred to as the secondary dystroglycanopathies. Mutations in up to 18 genes have
now been associated with this group, including POMT1 [20], POMT2 [21], POMGnT1 [22,
23], Large [12, 24], FKTN [10, 25, 26], FKRP [27], DPM1, DPM2 [28, 29], ISPD [9, 30, 31],
GTDC2 [32], TMEM5 [9], B3GNT1 [33], DOLK [34], SGK196 [35], GMPPA and GMPPB [36,
37]. Mutations in these genes give rise to a wide spectrum of clinical phenotypes of varying
severity: Walker-Warburg syndrome and Muscle-Eye-Brain disease are invariably fatal, while
mutations leading to congenital muscular dystrophies (CMD) can affect muscle alone, or pres-
ent with ocular and central nervous system defects (including cortical malformations such as
polymicrogyria and cobblestone lissencephaly). Even limb-girdle muscular dystrophies
(LGMD) can vary in disease progression and severity. With respect to Large (like-acetylgluco-
saminyltransferase), to date 15 patients with mutations in this gene have been reported and
whilst these patients display a wide clinical phenotype they all present with brain involvement
[38].
Post-translational addition of the polysaccharide repeating unit [-3-xylose-α1,3-glucuronic
acid-β1-]n by the dual-function LARGE glycosyltransferase both increases and enhances the
binding capacity of α-DG for extracellular matrix ligand [39], and some years ago LARGE was
shown to be able to compensate for an absence or reduction of POMT1, POMGnT1, fukutin or
FKRP although subsequent work showed that this depended on presence of residual α-DG O-
mannosylation [40]. This stimulated much interest in the value of LARGE up-regulation as a
therapeutic agent in these disorders and promisingly it was shown that its over-expression in
wild type mice seemed to cause only a sub-clinical phenotype in older mice [41]. However,
overexpressing LARGE in a FKRP deficient model unexpectedly resulted in a worsening of the
muscle pathology [42], and similar outcomes were observed with LARGE expression in lami-
nin α2 deficient (dy/dy) mice and conditional knock-outs for fukutin [43–45]. A greater under-
standing of the mechanisms underlying this exacerbation is critical to the development of
effective future therapies using LARGE or other agents to hyperglycosylate α-DG.
In this study we sought to determine whether the deleterious phenotype we previously
reported following LARGE overexpression in FKRP-deficient muscle was a sufficiently-gen-
eralised phenomenon such that it would manifest even under conditions where deficiency in
LARGE represented the sole defect. In order to do this we crossed the same LARGE trans-
genic line [41] as used in the previous study [42] with the LARGEmyd mouse which carries a
deletion of exons 5–7 of the Large gene, resulting in frameshift and a concomitant premature
termination codon (PTC) [24]. LARGEmyd mice display a muscular dystrophy phenotype in
addition to both cortical and cerebellar abnormalities [12, 24], presenting at the phenotypic
level as reduced lifespan, pronounced kyphosis, muscle atrophy and a characteristic hindlimb
paralysis.
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We show here that transgenic expression of human LARGE on the LARGEmyd background
restores a normal phenotype and wholly corrects both the muscle pathology and the abnormal-
ities seen in the brain, despite dramatic tissue-specific differences in transgene expression level
and extent of α-DG hyperglycosylation. Our data suggests LARGE-mediated hyperglycosyla-
tion of muscle α-DG is well-tolerated, and may indeed only be deleterious under conditions of
continuous muscle regeneration (i.e those caused by additional glycosylation defects such as a
loss/reduction of FKRP activity). We further show, however, that this non-physiological hyper-
glycosylation is not necessarily required for functional recovery. This work has important
implications for future therapeutic strategies, suggesting LARGE dosing is highly permissive,
and that the crucial factor determining the efficacy of LARGE up-regulation in the dystroglyca-
nopathies is the primary gene defect rather than the level of transgene expression.
Materials and Methods
All reagents were supplied by Sigma unless stated otherwise.
Mice
All mice used for this study (Wild type, LARGEmyd, LARGEmyd-LV5 andWT-LV5 genotypes
-LV5 suffixes indicating presence of the human LARGE transgene [41]) are on a predominantly
C57BL6/J background (5–7 back-crossings). Animal experiments were carried out under license
from the Home Office (UK) in accordance with The Animals (Scientific Procedures) Act 1986
and were approved by the Royal Veterinary College ethics and welfare committee.
A total of 52 mice were used for this study: 10–15 mice per genotype in approximately equal
ratios of males and females, collected at 10–22 weeks of age. No sex or age-dependent differ-
ences were observed in any genotype in the relevant parameters measured.
Sample preparation. Mice were killed by cervical dislocation and tissues harvested rap-
idly. Tissues for protein/RNA analysis were flash-frozen in liquid nitrogen. For histology skele-
tal muscle was mounted in cryo-M-bed (Bright) on cork blocks and frozen under liquid
nitrogen-cooled isopentane. In order to preserve tissue morphology brain tissue was fixed in
paraformaldehyde, dehydrated and paraffin wax-embedded. Samples were serial sectioned at
10 μm (frozen muscle) and 5μm (paraffin wax embedded brain), with sections collected onto
charged slides (Superfrost Plus, VWR). Haematoxylin and eosin staining was carried out using
standard protocols.
Histology
Brains. Coronal sections of brains were examined at five levels–the cerebral cortex at the
levels of the optic chiasm and the posterior hypothalamus, the pons, the midcerebellum and
the medulla oblongata. Sections were deparaffinised, rehydrated, and either stained with hae-
matoxylin and eosin, or taken through heat-induced epitope retrieval (HIER) for immunohis-
tochemistry using antibodies to glycosylated α-DG (IIH6, Millipore) and to β-DG (Clone 56,
BD biosciences). HIER was performed in Tris-EDTA (10 mM Tris-HCl, 1 mM disodium
EDTA, pH 8.0). Primary antibodies were diluted in phosphate buffered saline containing
0.05% tween 20 and 5% goat serum to 1:200 (IIH6) or 1:100 (βDG) and incubated on sections
for 1 hour at room temperature. Visualisation of antibody binding used Envision (DAKO).
Skeletal Muscle. Sections of quadriceps muscles were either stained with haematoxylin
and eosin or immunostained using IIH6 and β-DG antibodies (as above) with AlexaFluor (488
and 594) conjugated secondary antibodies. Nuclei were resolved using Hoechst staining. Pho-
tomicrographs of colorimetric-stained sections were captured on a Leica DM4000B brightfield
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microscope using a Leica DC500 camera. Immunofluorescent images were captured on a Leica
DM4000 fluorescence microscope using a monochrome camera.
Preparation of tissue lysates
Flash-frozen tissues (whole brains, quadriceps muscle) from individual mice were pulverised
under liquid nitrogen using a mortar and pestle, and subsequent powdered tissue (ca. 50-
100mg per sample) was added directly to lysis buffer containing 1% (vol/vol) Triton X-100,
0.1% (wt/vol) SDS supplemented with Complete mini Protease Inhibitors (Roche). Samples
were incubated on ice for 1 hour then boiled for 5 min. Insoluble material was removed by cen-
trifugation (13,000 rpm for 15 min at 4°). Lysate protein levels were measured using the BCA
kit (Pierce), and stored at -80 for use in western blotting.
Western Blotting
Tissue lysates (10-25ug.lane-1) were run on precast acrylamide gradient gels (3–8%, Invitro-
gen) and transferred to PVDF membranes using wet blotting. Blots were blocked for 1 hour in
5% milk (Marvel) in TBS-T (TBS supplemented with 0.5% Tween 20) before probing with
IIH6 (Millipore) at 1/100 in 5% milk TBS-T, followed by HRP-conjugated anti-mouse IgM (1/
100000). Blots were developed using ECL prime and visualised using Hyperfilm (Amersham)
or a ChemiDoc MP imaging system (BioRad).
Cell culture
H2KSF1 and H2K2B4 (mdx and WT immortomouse-derived cell lines, respectively) were
grown in matrigel-coated flasks (0.1mg.ml-1) and maintained in a proliferative state by incuba-
tion at 33°C in proliferation medium: DMEM+glutamax (invitrogen) supplemented with 20%
(v/v) heat inactivated-foetal bovine serum, 2% (v/v) chicken embryo extract (CEE, Sera labora-
tories international), 1% (v/v) Penicillin/Streptomycin (Sigma, final concentration 100u.ml-1
penicillin, 100ug.ml-1 streptomycin), and 20 U/mL γ-IFN (Chemicon). One day prior to differ-
entiation, cells were seeded onto matrigel-coated 6-well plates at 2x105 cells.well-1 (2B4) and
5x105 cells.well-1 (SF1), plating conditions established to allow optimal differentiation without
under- or overcrowding cells. Differentiation was initiated by replacement of growth media
with differentiation medium (DMEM+glutamax supplemented with 5% horse serum (PAA)
and 1% pen/strep) and incubation at 37°C. Differentiation medium was partially replaced
(50% of medium aspirated, replaced with fresh differentiation medium) after 5 days of
differentiation.
RNA isolation and cDNA synthesis
Flash-frozen tissues (brains, hearts, quadriceps muscle) were pulverised under liquid nitrogen
using a mortar and pestle, and subsequent powdered tissue (ca. 100mg per sample) was used to
prepare RNA using TRIzol reagent. Myoblast/myotube cell cultures were harvested by cell
scraper into TRIzol directly. RNA was prepared according to the manufacturer’s protocol with
an additional chloroform extraction step (1:1 vol/vol) added prior to precipitation. Samples
were analysed via denaturing agarose gel for presence of two sharp ribosomal bands, and RNA
quality was measured via nanodrop spectrophotometry to ensure 260/230 ratios higher than
1.8 (typically> 2.0), and 260/280 ratios of 1.9–2.0. Samples with a 260/230 ratio lower than 1.8
were cleaned via an additional ethanol precipitation (0.1 vols 3M NaAc pH 5.5, 10ug glycogen,
3 vols ice cold ethanol, -80 degrees for 1 hour).
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cDNA was prepared from 0.8-1ug of RNA, using the RTnanoscript kit (PrimerDesign) with
oligo dT and random priming.
Quantitative PCR
Primers for endogenous LARGE (mLarge), the LARGE LV5 transgene (hLarge) and endoge-
nous LARGE2 (mLarge2) were designed using Primer3 (primer3.ut.ee). PCR products were
typically 80-200bp in length, and designed to span one or more introns (where possible) to pre-
vent amplification of genomic DNA. Primer sequences were selected to minimise cross-reactiv-
ity, as mouse LARGE, human LARGE and mouse LARGE2 transcripts share a high degree of
sequence identity. Several primer sets were designed for LARGE2 (see S1 Sequences), though
we did not detect LARGE2 transcript in any tissues described here. Primers to Csnk2a2,
Pak1ip1, Htatsf1, Ap3d1 and Zfp91 form part of the geNormPlus kit, and are proprietary prop-
erty of PrimerDesign.
mLarge exon14 F1: CTCACATTCATGGAATTGGATGCA
mLarge exon15 R1: TGGTGGCTCTCCCTAGTAGT
hLarge 5UTR F1: GAGCTCGGATCCACTAGTCC
hLarge 5UTR R1: CGAAGCTCCCAGAAAACAGG
qPCR runs used Precision SYBR green mastermix (Primerdesign) in white hard-shell
384-well plates (BioRad) using 5-10ng of cDNA per well in a BioRad CFX384. Cq values for
LARGE and LARGE LV5 were converted to relative quantities (or transcript numbers as
described below) and normalised to the geometric mean of two or three suitable reference
genes (as determined by geNorm and Normfinder): Cell culture: Cnsk2a2 and Ap3d1, Heart
and quadriceps: Pak1ip1 and Ap3d1, Brain: Pak1ip1, Htatsf1 and Zfp91. Mean expression lev-
els per tissue of the shared reference gene (Pak1ip1) were used to calibrate normalisation fac-
tors to determine relative transcript levels across tissues. Cq values were typically between 20
and 27 for both reference genes and genes of interest (though as low as 17 for LARGE LV5 in
heart/quadriceps).
Estimations of transcript numbers were performed by qPCR using constant amounts of
sample cDNAs (or water) mixed with a standard dilution series (107−100 molecules.well-1) pre-
pared from purified PCR product of known concentration. As cDNA is predominantly single-
stranded an additional cycle is required for parity with PCR products, thus the concentration
(in molecules.well-1 of standard) at which the dilution series (+cDNA) plateaus corresponds to
approximately half the cDNA concentration.
Statistics
P values in figure legends refer to statistical calculations performed using multiple comparisons
tests (Dunn’s or Holm-Sidak’s as appropriate with respect to data normality and N value).
Results
Transgenic overexpression of LARGE restores glycosylation of α-DG in
both muscle and brain of LARGEmyd mice, and corrects both the muscle
and brain defects
Wild type mice carrying the LARGE-LV5 transgene (WT-LV5) are indistinguishable from
non-transgenic littermates [41], while homozygous LARGEmyd mice are readily identified by
their smaller size, pronounced kyphosis and distinctive gait abnormalities [12]. LARGEmyd
mice carrying the LARGE-LV5 transgene (LARGEmyd-LV5), generated for this study, appear
wholly normalized, being essentially identical in appearance to WT or heterozygote littermates.
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Western blotting of tissue lysates prepared fromWT, WT-LV5, LARGEmyd and LARGE-
myd-LV5 transgenic mice with the antibody IIH6 (which recognizes the laminin-binding epi-
tope of α-dystroglycan) demonstrated restoration of glycosylation on α-DG in LARGEmyd-
LV5 transgenic mice (Fig 1). The muscles of LV5 transgenic LARGEmyd mice demonstrated
the greatly enhanced IIH6-reactivity characteristic of hyperglycosylation, as did WT-LV5 mice
(as previously published [41]). Interestingly the brains of LV5-transgenic WT and LARGEmyd
mice did not display obvious hyperglycosylation, implying a significant tissue-specific variation
in LARGE-LV5 transgene expression.
Skeletal muscle immunohistochemistry confirmed that transgenic expression of LARGE
restored IIH6 reactivity in LARGEmyd mice, and that the IIH6 epitope was correctly localised to
the sarcolemma (Fig 2). Both WT-LV5 and LARGEmyd-LV5 muscles demonstrated enhanced
IIH6 reactivity characteristic of hyperglycosylation.
LARGEmyd mice typically demonstrate progressive, severe muscle pathology, with extensive
fibrotic and adipose infiltrates, increased fibre size variation and large numbers of hypercon-
tractile and centrally nucleated fibres. Muscles from LARGEmyd-LV5 mice exhibit no visible
hypercontractility, infiltration or scarring, and wild-type levels of central nucleation (Fig 3),
demonstrating that the muscle phenotype is wholly corrected and further that hyperglycosyla-
tion of α-DG appears to have no adverse effects in this tissue.
The brains of adult LARGEmyd mice typically exhibit lesions characteristic of a neuronal
migration defect, with fusion of the interhemispheric fissure and loss of normal cortical lami-
nation. Within the cortex, ectopic neurons infiltrate the marginal zone and form a narrow,
multifocal extracortical layer. In addition, normal lamination in the cerebellum is lost, and
large clusters of ectopic granule cells are present between the molecular layer and the pia. Hae-
matoxylin and eosin staining (Figs 4 and 5, S1 and S2 Figs) revealed that the brains of both
WT-LV5 and LARGEmyd-LV5 transgenic mice were essentially histologically indistinguishable
fromWTmice, the only exception being the presence of small focal aggregates of ectopic gran-
ule cells (less than 5 cells) that were observed between the molecular layer and the pia within
the cerebellum of all LARGEmyd-LV5 brains but only a single WT brain (n = 6).
IIH6 immunoreactivity in WT brains primarily localises to the vascular and pial basement
membranes and the choroid plexus: while choroid plexus staining is retained in LARGEmyd
mice [8], IIH6 immunoreactivity is absent in all other areas (Fig 6, S1 and S2 Figs). Transgenic
expression of LARGE in LARGEmyd-LV5 brains restored a WT staining pattern, though diffuse
global immunoreactivity was also observed in both LARGEmyd-LV5 and WT-LV5 brains.
Staining for β-DG was of similar pattern and intensity between WT, LARGEmyd-LV5 and
WT-LV5 mice. Interestingly LARGEmyd mice exhibited a marked decrease in staining intensity
of β-DG specifically at vascular basement membranes, while also exhibiting faint diffuse stain-
ing of the cerebellar molecular layer (S1 and S2 Figs). Expression of β-DG at the pial basement
membrane and in the epithelium of the choroid plexus was similar to that observed in the
other groups. Taken together, histopathological and immunohistochemical findings indicate
that expression of the LARGE-LV5 transgene in the LARGEmyd mouse rescues the brain phe-
notype, both structurally and at the protein level.
Levels of transgenic LARGE transcript are close to physiological values
in brain, but dramatically overexpressed in muscle and heart
Previous studies have shown that levels of both endogenous LARGE and the LARGE-LV5
transgene vary significantly from tissue to tissue: endogenous LARGE expression was shown to
be high in the brain, relatively low in heart and lower still in skeletal muscle, while in marked
contrast expression of the transgene was high in skeletal muscle, low in heart and lower still in
Transgenic Rescue of the LARGEmyd Mouse
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Fig 1. The LARGE-LV5 transgene restores IIH6 reactivity, and causesmarked hyperglycosylation in
muscle. IIH6 western blot of tissue lysates from brain (a) and quadriceps muscle (b) of WT and LARGEmyd
mice with or without the LARGE-LV5 transgene (as indicated). β-dystroglycan included as loading control.
doi:10.1371/journal.pone.0159853.g001
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brain [41]. These studies, however, only address the relative levels of each transcript in different
tissues and do not therefore allow direct comparison of endogenous expression with transgene
transcript levels. To determine this relationship precisely we used quantitative PCR (qPCR) to
obtain values for absolute number of transcripts in brain, heart and muscle.
As shown in Fig 7, qPCR analyses confirmed that LARGE transgene expression driven by
the CAGGs promoter demonstrates significant tissue specificity, achieving levels of expression
Fig 2. The LARGE-LV5 transgene restores IIH6 reactivity. Immunostaining of quadriceps muscle fromWT
and LARGEmyd mice with or without the LARGE-LV5 transgene (as indicated). Upper panel: IIH6, Lower
Panel: β-Dystroglycan.
doi:10.1371/journal.pone.0159853.g002
Transgenic Rescue of the LARGEmyd Mouse
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in heart and skeletal muscle over an order of magnitude greater than in brain (Fig 7b). Con-
versely, while levels of endogenous transcript were greatly reduced in LARGEmyd mice (as
expected for PTC-carrying mRNAs), expression of endogenous LARGE inWT/WT-LV5 mice
is 2- or 5-fold higher in the brain than heart or skeletal muscle, respectively (Fig 7a). As a
Fig 3. The LARGE-LV5 transgene corrects LARGEmyd muscle pathology.Haematoxylin/Eosin staining
of quadriceps muscle from LARGEmyd (a) and LARGEmyd plus the LARGE-LV5 transgene (b). Extent of
muscle central nucleation in the genotypes indicated (c). Means+SEM, N = 3. ** P<0.01.
doi:10.1371/journal.pone.0159853.g003
Transgenic Rescue of the LARGEmyd Mouse
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consequence, levels of LARGE expression in the brains of LARGEmyd mice carrying the LV5
transgene are comparable with those in WTmice (approx. 1300 transcripts.ng-1 cDNA–dashed
line, Fig 7b), while transgene expression in the heart and skeletal muscle can reach levels almost
100-fold greater than endogenous muscle equivalents (ca. 20000 vs 200–800). Expression of the
LARGE paralog LARGE2 was not detected in either brain or muscle inWT, WT-LV5, LARGE-
myd or LARGEmyd-LV5 mice, thus LARGE2 is unlikely to play a role in α-DG glycosylation in
either tissue in the adult. The dramatic skeletal muscle overexpression of the LARGE transgene
shown here thus likely underpins the hyperglycosylation of α-DG observed in this tissue.
Expression of endogenous LARGE follows differentiation cues,
increasing during myogenesis in both healthy and dystrophic cells
Expression of LARGE has been reported to increase during muscle regeneration [39], suggest-
ing a role for this glycosyltransferase in myogenesis. To investigate expression of endogenous
LARGE throughout myogenic differentiation under both healthy and dystrophic conditions,
we used the immortomouse cell lines H2K2B4 and H2KSF1, the latter of which carries themdx
mutation (the mouse model of Duchenne muscular dystrophy). As shown in Fig 8, expression
of LARGE increases over a near-identical time-course in both healthy and dystrophic cultures
as cells progress from proliferating myoblasts to large multinucleate myotubes, suggesting
expression of LARGE mirrors myogenic progression even in dystrophic myofibres.
Discussion
Despite promising results in cell culture models of secondary dystroglycanopathies [40], previ-
ous work by our group has demonstrated that overexpression of LARGE on a FKRP-deficient
Fig 4. The LARGE-LV5 transgene corrects LARGEmyd cortical defects.Haematoxylin/Eosin staining of
cortical coronal sections of brains from wild type, WT-LV5, LARGEmyd and LARGEmyd-LV5 mice (as
indicated). WT andWT-LV5 mice display normal laminar cortical arrangement, with a clear molecular layer
which is lost in LARGEmyd but restored by the LARGE-LV5 transgene (arrowheads). Bar: 200μm.
doi:10.1371/journal.pone.0159853.g004
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background is deleterious [42]. In marked contrast we show here that transgenic overexpres-
sion of human LARGE on the LARGEmyd background corrects the LARGEmyd phenotype in
both the skeletal muscle and brain. This is despite a similar pattern of α-DG hyperglycosylation
(as judged by both immunocytochemistry andWestern blotting) as that observed on the
FKRP-deficient background. Relative expression levels of endogenous LARGE and the LAR-
GE-LV5 transgene between tissues are in agreement with previously published data [41], how-
ever we also quantified absolute levels of expression and demonstrate that while endogenous
and transgene expression levels in brain are highly comparable, heart and skeletal muscle (with
their lower endogenous LARGE expression) display a dramatic fold increase in LARGE tran-
scripts, with the transgene expressed at a level almost 2 orders of magnitude greater than
endogenous LARGE.
It is important to note that we would not necessarily expect increases in LARGE protein to
be of commensurate magnitude with increases in transcript levels in transgenic animals: the
LARGE-LV5 transcript does not share 5’ or 3’ UTR sequence with endogenous LARGE
Fig 5. The LARGE-LV5 transgene corrects LARGEmyd cerebellar defects. Haematoxylin/Eosin staining
of cerebellar sections of brains from wild type, WT-LV5, LARGEmyd and LARGEmyd-LV5 mice (as indicated).
The molecular layer (black arrowhead) and granular cell layer (white arrowhead) are readily apparent in WT
andWT-LV5mice, with a single layer of large Purkinjie cells sandwiched between them. In LARGEmyd mice,
the granular cell layer is extensively disrupted with large aggregates of ectopic granule cells superficial to the
molecular layer (asterisks). This disruption is corrected, and ectopic granule foci greatly reduced, in the
LARGEmyd-LV5 mice. Bar: 200μm.
doi:10.1371/journal.pone.0159853.g005
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Fig 6. The LARGE-LV5 transgene restores IIH6 reactivity and confers a diffuse global increase in the
epitope in brains. IIH6 immunostaining of cerebellar sections of brains from wild type, WT-LV5, LARGEmyd
and LARGEmyd-LV5 mice (as indicated). IIH6 reactivity is observed in blood vessels and the pia in WT,
WT-LV5 and LARGEmyd-LV5 cerebellum, but not in brains of LARGEmyd mice. Overall stain intensity is higher
in LV5 transgenic mice than in WT controls. Bar: 200μm.
doi:10.1371/journal.pone.0159853.g006
Fig 7. Levels of transgenic LARGE transcript are equivalent to endogenous expression in brain, but
greatly overexpressed in heart and skeletal muscle. qPCR analysis of cDNA prepared from brain, heart
and quadriceps (from genotypes as indicated) using primers for endogenous LARGE (a) or the LARGE-LV5
transgene (b). Quantities are shown as mean number of transcripts per ng cDNA (+ S.E.M, N = 5–9). Dashed
line in (b): expression level of endogenous LARGE in brain. ** P<0.01, *** P<0.005, **** P<0.001. No
significant differences in endogenous expression within a given tissue were detected betweenWT and
WT-LV5, or in transgene expression betweenWT-LV5 and LARGEmyd-LV5, for any of the tissues studied.
doi:10.1371/journal.pone.0159853.g007
Transgenic Rescue of the LARGEmyd Mouse
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Fig 8. Expression of endogenous LARGE increases during myogenesis in both normal and
dystrophic cells. qPCR analysis of cDNA prepared fromWT (H2K2B4) ormdx (H2KSF1) cell cultures at the
times indicated using primers for endogenous LARGE (upper panel), and for myogenic transcription factors
MyoD and MEF2C (lower panels). Expression levels are normalised (using Csnk2a2 + Ap3d1) and shown as
fold increase over time-zero (proliferating) levels (Means + S.E.M, N = 3).
doi:10.1371/journal.pone.0159853.g008
Transgenic Rescue of the LARGEmyd Mouse
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transcripts, and these elements (which are of considerable length in the endogenous LARGE
mRNA) may influence translation efficiency, stability and subcellular trafficking of the tran-
script. It is nevertheless reasonable to expect a limited degree of correlation between protein
and transcript level, and thus LARGE protein levels are likely to be substantially higher in
transgenic muscle than in WT muscle or LV5 transgenic brain tissue.
Our data therefore suggests the α-DG hyperglycosylation observed in transgenic muscle is a
consequence of supra-physiological levels of LARGE activity within this tissue (rather than tis-
sue-specific variability in suitable LARGE glycosylation targets) but also suggests that to correct
the LARGEmyd phenotype in brain, LARGE-LV5 need only be expressed at physiologically-
equivalent levels.
Given the nature of our analyses, this observation is somewhat unexpected. The brain is a
highly-organised tissue with multiple domains of discrete architecture: in WT brains IIH6
staining is restricted to relatively well-defined regions (primarily the vascular and pial base-
ment membranes and the choroid plexus), implying strict spatio-temporal control. In contrast,
expression of the LARGE-LV5 transgene is driven by the relatively potent constitutive CAGGs
promoter. Whilst this promoter clearly confers tissue-specific variation in absolute expression
level, it is nevertheless likely to be expressing at some level, constitutively, in virtually all cells.
Immunostaining of LV5 transgenic brains reveals globally elevated IIH6 reactivity (Fig 6, S1
and S2 Figs), indicating that LARGE upregulation is not subdomain-restricted. This is further
supported by the observation that LV5 mice even demonstrate IIH6 reactivity in the testis, a
tissue usually IIH6-negative (S3 Fig).
Our analysis of gene expression here reflects the total mRNA level in whole adult brain tis-
sue, precluding identification of spatial or temporal variations in gene expression. This is in
contrast to muscle, where much of the tissue bulk is comprised of comparatively transcription-
ally-uniform myofibres, with specialised regions such as the neuromuscular and myotendinous
junctions making only a minor contribution to the transcriptional milieu of a given whole mus-
cle extraction. Measured transcript levels are thus likely a more accurate reflection of homoge-
nous expression in muscle than in brain. With this caveat accepted, the observation that total
transgene transcript levels in the brains of LARGEmyd-LV5 animals are essentially equivalent
to those of endogenous LARGE, coupled with the widespread histological IIH6 immunoreac-
tivity LV5-transgenic animals demonstrate, suggests that LARGE expression in LARGEmyd-
LV5 mice does not recapitulate wild-type expression patterns: being low-level and relatively
uniform rather than high-level but restricted to specific regions of the tissue.
The phenotypically normal behaviour of WT-LV5 mice suggests that such low-level, wide-
spread and constitutive expression of transgenic LARGE, in the presence of normal expression
of endogenous LARGE, does not significantly hinder brain development. The corrected pheno-
type of LARGEmyd-LV5 mice, however, strongly suggests that such constitutive expression is in
fact sufficient to normalise brain development. That low, constitutive expression of LARGE
apparently restores normal brain development is thus highly encouraging, if perhaps surprising
(though the authors note that vascular IIH6 staining is prominent in WT, WT-LV5 and LAR-
GEmyd-LV5 brains, thus vasculature-derived LARGE transcripts may comprise a significant
percentage of total brain expression levels in both WT and transgenic animals, masking subtle
variations).
If LARGE is to function as a therapeutic, elucidation of appropriate dosing is critical. Simply
put: how much LARGE is enough? Levels of endogenous LARGE transcript are lower in muscle
than brain, and the binding properties of α-DG are different in these two tissues [46]. Taken
together, these observations tend to suggest that LARGE may fulfil different (albeit partially
overlapping) roles in brain and muscle. As demonstrated here, a 100-fold overexpression of
LARGE at the mRNA level is apparently sufficient to rescue the LARGEmyd muscle pathology,
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and moreover with no overt ill-effects. Indeed this same overexpression on a WT background
is similarly well-tolerated [41]. As assessed by IIH6 western blotting, this overexpression
unsurprisingly leads to hyperglycosylation of α-DG in muscle, while (as might be expected) the
near-physiological expression of the transgene in brain apparently does not (Fig 1). Quantita-
tion of this enhanced IIH6-reactivity would be of considerable benefit; however α-DG migrates
as a broad, highly diffuse band under SDS-PAGE (an effect yet more pronounced under condi-
tions of hyperglycosylation), making such assessment challenging. These limitations accepted,
we feel confident in suggesting that IIH6-reactivity is enhanced by considerably less than
100-fold in LV5-transgenic skeletal muscle. This raises a therapeutically-relevant question:
both brains and muscles of WT animals show similar levels of IIH6-reactivity, though as
shown here and previously [41] endogenous expression of LARGE mRNA is five-fold higher in
brain. Moreover, while a doubling of LARGE transcript appears to have little effect on IIH6-
reactivity in brain, a 100-fold increase in LARGE expression leads to a significant but non-
commensurate increase in muscle α-DG hyperglycosylation. In essence: why do transcript lev-
els correlate comparatively poorly with IIH6-reactivity?
A simple explanation (as discussed above) is that transcript levels need not correlate with
protein levels: a dramatic overexpression at the mRNA level may saturate the translation
machinery, or generate more LARGE protein than the Golgi can accommodate leading to deg-
radation. Another possibility lies in the fact that while LARGE is restricted to the Golgi, α-DG
resides on the extracellular leaflet of the plasma membrane: the interaction between LARGE
and α-DG is subject to spatial and temporal constraints, thus comparatively transient under
normal conditions. This interaction may thus be saturable: a finite exposure to the Golgi envi-
ronment places a limit on potential interaction and glycosylation events, implying a threshold
may exist above which additional LARGE protein is unable to contribute to α-DG glycosyla-
tion. Conversely, evidence for a physical interaction between LARGE and dystroglycan medi-
ated through the N-terminal domain of α-DG [47] raises the possibility that overexpressed
(Golgi-resident) LARGE protein might partially sequester dystroglycan, prolonging DG transit
through the Golgi and consequently extending exposure to not only the LARGE glycosyltrans-
ferase activity, but also additional Golgi-resident glycosyltransferases.
A further caveat to α-DG-focussed interpretations is that the effects (beneficial or other-
wise) of LARGE overexpression need not be wholly mediated through α-DG, or indeed via O-
mannosylation: it has been shown that overexpression of LARGE in neural stem cells confers
IIH6-reactive LARGE glycan epitopes even in the absence of POMT2 or dystroglycan itself
[48]. While at best only an approximation of physiological behaviour, this nevertheless high-
lights the risks of attributing IIH6-reactivity exclusively to α-DG, and suggests that (in neural
tissue at least) multiple targets are capable of accepting LARGE-conferred glycosylation, and
not necessarily in a manner dependent on phosphorylated O-mannose. The globally increased
IIH6-reactivity observed here in LARGE-LV5 transgenic brains may thus partially reflect non-
canonical glycosylation events: the LARGE protein possesses two structurally-distinct glycosyl-
transferase domains; a degree of promiscuous LARGE activity is not an unrealistic hypothesis.
A critical therapeutic question is why LARGE overexpression (and consequent α-DG hyper-
glycosylation) so effectively corrects the LARGEmyd muscle phenotype, when equivalent
LARGE overexpression on a FKRP-deficient background [42] is actively detrimental despite
promising behaviour in isolated cells. FKRP-deficient mice carrying the LARGE-LV5 transgene
show α-DG hyperglycosylation (suggesting FKRP is not an obligate requirement for addition
of LARGE glycans) yet nevertheless exhibit markedly exacerbated disease severity.
Aside from the obvious observation that only LARGE overexpression on a LARGEmyd back-
ground represents direct complementation, a clue may lie in the observation that LARGE
expression increases during myogenic differentiation in both normal and dystrophic cell
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cultures (Fig 8) and during muscle regeneration in vivo [39] and has been proposed to ‘tune’
the extent of interaction with the extracellular matrix environment through α-DG glycosyla-
tion. Repair of damaged muscle fibres requires a high degree of coordinated cell proliferation,
movement and fusion, and the extracellular matrix of the muscle tissue provides a partial scaf-
fold to organise these processes. While the absence of LARGE at any stage leads to α-DG hypo-
glycosylation and pronounced progressive muscle degeneration, lower (but crucially non-zero)
levels of α-DG glycosylation in early differentiation may facilitate myoblast migration and
myotube fusion by limiting interaction with matrix components, easing progress through the
extracellular environment.
LARGE overexpression (with concomitant α-DG hyperglycosylation) might therefore lead
to the reverse, enhancing interaction with the extracellular matrix effectively constitutively,
impeding cell movement and hampering regeneration. The phenotypically normal appearance
and function of muscle fromWT-LV5 or LARGEmyd-LV5 mice implies that LARGE overex-
pression does not impair muscle development, thus this effect might be restricted to regenera-
tion alone. We conjecture that detrimental effects of LARGE overexpression may only
manifest in the presence of additional muscle defects that necessitate regeneration. WT/LAR-
GEmyd mice with the LARGE LV5 transgene (having normal/corrected muscle, respectively)
should have wild-type levels of resistance to muscle damage, minimal degeneration and thus
limited opportunity to demonstrate a regenerative defect (interestingly, aged WT-LV5 mice do
exhibit a mild dystrophic phenotype, possibly representing steady accumulation of poorly-
regenerated but sub-clinical muscle damage events [41]). In contrast, FKRP-deficient LAR-
GE-LV5 transgenic mice carry different–uncorrected- defects and thus may still be subject to
muscle damage and degeneration (even in the presence of a strengthened interaction between
the sarcolemma and the extracellular matrix), allowing the LARGE overexpression-mediated
regenerative defect to present, exacerbating disease pathology. Indeed, recently published find-
ings by Saito et al [45] support this hypothesis.
In conclusion, the data presented here add support to the viability of LARGE as a potential
therapeutic: transgenic expression of LARGE in the LARGEmyd mouse wholly corrects both
the brain and muscle phenotype in this animal model, despite stark tissue-specific differences
in expression level of the transgene. The observation that broadly distributed, low-level expres-
sion of LARGE is apparently sufficient to rescue brain morphology suggests substantial overex-
pression or up-regulation is not necessary for functional restoration, while our muscle analyses
demonstrate that dramatic (100-fold) LARGE overexpression–with concomitant α-DG hyper-
glycosylation- is both sufficient to restore muscle function and also apparently well-tolerated
in the absence of additional glycosylation defects (such as the absence of FKRP). Exogenous
expression of LARGE would thus appear to exhibit a very broad therapeutic window, providing
benefit over a wide expression range. As fine-tuning of gene dosing in gene therapy is non-triv-
ial, the permissive profile described here bolsters the case for the therapeutic use of LARGE.
Supporting Information
S1 Fig. LARGE-LV5 transgene corrects LARGEmyd cortical defects. Cortical coronal sections
of brains from wild type, WT-LV5, LARGEmyd and LARGEmyd-LV5 mice (as indicated). a-d:
Haematoxylin/Eosin staining. WT and WT-LV5 mice display normal laminar cortical arrange-
ment (arrowheads), which is lost in LARGEmyd but restored by the LARGE-LV5 transgene.
e-h: IIH6 immunostaining. IIH6 reactivity is observed in blood vessels and the pia in WT,
WT-LV5 and LARGEmyd-LV5 cortex but not in brains of LARGEmyd mice. Overall stain inten-
sity is higher in LV5 transgenic mice than in WT controls. i-l: β-DG immunostaining. Blood
vessels are visible in cortex of WT, WT-LV5 and LARGEmyd-LV5 cortex but not in brains of
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LARGEmyd mice. Bars represent 200μm. White boxes: image subsections shown in Fig 4 (see
main text).
(TIF)
S2 Fig. LARGE-LV5 transgene corrects LARGEmyd cerebellar defects. Cerebellar sections of
brains from wild type, WT-LV5, LARGEmyd and LARGEmyd-LV5 mice (as indicated). a-d:
Haematoxylin/Eosin staining. In WT and WT-LV5 mice (a, b), the molecular layer (Black
arrowhead) and granular cell layer (White arrowhead) are readily apparent, with a single layer
of large Purkinjie cells sandwiched between them. In LARGEmyd mice (c), the granular cell
layer is extensively disrupted with large aggregates of ectopic granule cells superficial to the
molecular layer (asterisks). This disruption is corrected, and ectopic granule foci greatly
reduced, in the LARGEmyd-LV5 mice (d). e-h: IIH6 immunostaining. IIH6 reactivity is
observed in blood vessels and the pia in WT, WT-LV5 and LARGEmyd-LV5 cerebellum, but
not in brains of LARGEmyd mice. Overall stain intensity is higher in LV5 transgenic mice than
in WT controls. i-l: β-DG immunostaining. Pia and blood vessels are visible in the cerebellum
of WT, WT-LV5 and LARGEmyd-LV5 mice but not in LARGEmyd mice. LARGEmyd mice
instead display a diffuse, indistinct staining of the molecular layer. Bars represent 200μm.
White boxes: image subsections shown in Figs 5 and 6 (see main text).
(TIF)
S3 Fig. LARGE-LV5 transgene confers IIH6 reactivity upon testis. IIH6 western blot of tis-
sue lysates from testis of WT, LARGEmyd and LARGEmyd-LV5 mice (as indicated).
(TIF)
S1 Sequences. qPCR primers used for LARGE2.
(DOC)
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